Fluoroquinolones in urinary tract infections. Proper and improper use

Drugs

Volumn 52, Issue SUPPL. 2, 1996, Pages 27-33

  Naber, Kurt G ^a  

^a Urologische Klinik   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMINOPENICILLIN; AZITHROMYCIN; BETA LACTAMASE INHIBITOR; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; ENOXACIN; FLEROXACIN; FOSFOMYCIN; LOMEFLOXACIN; MACROLIDE; NITROFURANTOIN; NORFLOXACIN; PEFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TRIMETHOPRIM; TROVAFLOXACIN; UREIDOPENICILLIN;

ACUTE PYELONEPHRITIS; ANTIBACTERIAL ACTIVITY; CHRONIC PROSTATITIS; CONFERENCE PAPER; CYSTITIS; DRUG CONTRAINDICATION; DRUG HALF LIFE; DRUG POTENCY; DRUG USE; HUMAN; ORAL DRUG ADMINISTRATION; URETHRITIS; URINARY TRACT INFECTION;

EID: 0029821503     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199600522-00006     Document Type: Conference Paper

References (40)

1. Naber KG, Wittenberger R. In-vitro-Aktivität von Gyrase-Hemmern gegenüber Erregern von komplizierten Harnwegsinfektionen. Fortschritte der Antimikrobiellen und Antineoplastischen Chemotherapie (FAC) 1987; 6-10: 1801-9
2. Naber KG, Witte W, Bauernfeind A, et al. Resistenzentwicklung gegenüber Fluorochinolonen. Untersuchungen mit Erregern von Patienten mit komplizierten Harnwegsinfektionen. Chemotherapie Journal 1993; 2: 106-11
3. Naber KG. Uncomplicated urinary tract infections - is single-dose therapy effective? Int J Antimicrob Agents 1994; 4 Suppl. 2: 39-45
4. Gellermann HJ, Grote J, Peters-Haertel W, et al. Kurzzeit-Therapie von unkomplizierten Harnwegsinfektionen der Frau mit Ciprofloxacin. Med Welt 1988; 39: 1586-91
5. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 1993; 329: 753-6
6. Smellie JM, Ransley PG, Normand ICS, et al. Development of new renal scars: a collaborative study. BMJ 1985; 290: 1957-60
7. Naber KG, Bauernfeind A, Dietlein G, et al. Urinary pathogens and bacterial sensitivity in hospitalized urological patients based upon clinical aspects. Scand J Urol Nephrol 1987; Suppl. 104: 47-57
8. Naber KG, Witte W, Bauernfeind A, et al. Clinical significance and spread of fluoroquinolone resistant uropathogens in hospitalised urological patients. Infection 1994; 22 Suppl. 2: 122-7
9. Naber KG. Use of quinolones in urinary tract infections and prostatitis. Rev Infect Dis 1989; 11 Suppl. 5: S1321-37
10. Frankenschmidt A, Bischoff W, Naber KG, et al. Fleroxacin in the oral treatment of complicated urinary tract infections [poster no. 3144]. 19th International Congress of Chemotherapy: 1995 July 16-21: Montréal. Québec. Canada
11. Cross AS, Opal S, Kopecko D. Progressive increase in antibiotic resistance of Gram-negative bacterial isolates. Walter Reed Hospital, 1976 to 1980: specific analysis of gentamicin, tobramycin, and amikacin resistance. Arch Intern Med 1983; 143: 2075-80
12. Holder IA. Gentamicin resistant Pseudomonas aeruginosa in a burn unit. J Antimicrob Chemother 1986; 2: 309-11
13. Wagenlehner FME. Auftreten von Fluorochinolon-resistenten Erregern bei komplizierten Harnwegsinfektionen in Korrelation zu klinischen Aspekten, 1996; Inaugural-Dissertation: Medical School of Technical University of Munich, Germany. In press
14. Sauerwein D, Bauernfeind A. Klinische Erfahrungen bei Behandlung von Harnwegsinfektionen bei Querschnittgelähmten mit Norfloxacin. Fortschritte der Antimikrobiellen und Antineoplastischen Chemotherapie (FAC) 1984; 3-5: 754-64
15. Kumon H, Ono N, Iida M, et al. Combination effect of fosfomycin and ofloxacin against Pseudomonas aeroginosa growing in a biofilm. Antimicrob Agents Chemother 1995; 39: 1038-44
16. Goto T, Nakame Y, Nishida M. In vitro and in vivo bactericidal effects of antibiotics on Pseudomonas aeroginosa biofilm in the urine [abstract no. 0671]. 19th International Congress of Chemotherapy: 1995 July 16-21: Montréal, Québec, Canada
17. Kumamoto Y, Nishimura M, Sano M, et al. Clinical study of combination therapy with clarithromycin and ciprofloxacin for complicated urinary tract infection as biofilm diseases [abstract no. 0317]. 14th International Congress of Chemotherapy 1995: July 16-21: Montréal, Québec, Canada
18. Peeling RW, Ronald AR. Use of quinolones in sexually transmitted diseases. In: Hooper DC, Wolfson JS, editors. Quinolone antimicrobial agents. 2nd ed. 1993: American Society for Microbiology, Washington DC, USA: 299-327
19. Grandsen WR, Warren CA, Phillips I, et al. Decreased susceptibility of Neisseria gonorrhoeae to ciprofloxacin. Lancet 1990; 335: 51
20. Oriel JD. Male genital Chlamydia trachomatis infections. J Infect 1992; 25 Suppl. 1: 35-7
21. Ridgway GL. Advances in the antimicrobial therapy of Chlamydial genital infections. J Infect 1992; 25 Suppl. 1: 51-9
22. Fong IW, Linton W, Simbul M, et al. Treatment of nongonococcal urethritis with ciprofloxacin. Am J Med 1987; 82 Suppl. 4a: 311-6
23. Hooton TM, Rogers E, Medina TG, et al. Ciprofloxacin compared with doxycycline for nongonococcal urethritis. JAMA 1990; 264: 1418-21
24. Nilsen A, Halsos A, Johansen A, et al. A double blind study of single dose azithromycin and doxycycline in the treatment of Chlamydial urethritis in males. Genitourin Med 1992; 68: 325-7
25. Meares Jr EM. Prostatitis syndromes: new perspectives about old woes. J Urol 1980; 123: 141-7
26. Stamey TA, Meares Jr EM, Winningham DG. Chronic bacterial prostatitis and the diffusion of drugs into prostatic fluid. J Urol 1970; 103: 187-94
27. Hanus PM, Danzinger LH. Treatment of chronic bacterial prostatitis. Clin Pharmacy 1984; 3: 49-55
28. Naber KG. Role of quinolones in treatment of chronic bacterial prostatitis. In: Hooper DC, Wolfson JS, editors. Quinolone antimicrobial agents. 2nd ed. 1993: American Society for Microbiology. Washington DC, USA: 285-97
29. Naber KG, Giamarellou H. Proposed study design in prostatitis. Infection 1994; 22 Suppl. 1: 59-60
30. van Poppel H, Willimen P, Wegge M, et al. Antibiotic cover of transurethral maneuvers with ciprofloxacin and susceptibility behavior of pathogens in patients with neurogenic bladder. Urol Int 1990; 45: 342-5
31. Hofer DR, Schaeffer AJ. Use of antimicrobials for patients undergoing prostatectomy. Urol Clin North Am 1990; 17: 595-600
32. Murphy DM, Falkiner FR, Carr M, et al. Septicaemia after transurethral prostatectomy. Urology 1983; 22: 133-5
33. Grabe M. Antimicrobial agents in transurethral prostatic resection. J Urol 1887; 138: 245-52
34. Larsen E, Gasser TC, Madsen PO. Antimicrobial prophylaxis in urologic surgery. Urol Clin North Am 1986; 13: 591-604
35. Finkelstein LH, Arsht DB, Manfrey SJ, et al. Ceftriaxone in the prevention of postoperative infection in patients undergoing transurethral prostatectomy. Am J Surg 1984; 148 Suppl. 4A: 19-21
36. Viitanen J, Talja M, Jussila E, et al. Randomized controlled study of chemoprophylaxis in transurethral prostatectomy. J Urol 1993; 150: 1715-7
37. Hargreave TB, Botto H, Rikken GHJM, et al. European collaborative study of antibiotic prophylaxis tor transurethral resection of the prostate. Eur Urol 1993; 23: 437-43
38. Raz R, Ahnog D, Elhanan G, et al. The use of ceftriaxone in the prevention of urinary tract infection in patients undergoing transurethral resection of the prostate (TUR-P). Infection 1994; 22: 347-9
39. Shearman CP, Silverman SH, Johnson M, et al. Single dose, oral antibiotic cover for transurethral prostatectomy. Br J Urol 1988; 62: 434-8
40. Gasser TC. Transurethral resection of the prostate. Western Pacific Congress on Chemotherapy and Infectious Diseases [abstract no. 31]. 7th European Congress of Clinical Microbiology and Infectious Diseases: 1995 Mar 26-30: Vienna, Austria